Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger ...

The FDA has approved teclistamab (Tecvayli) daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of patients with relapsed or refractory multiple myeloma following at least 1 line of ...

The most frequent treatment-emergent AEs for belzutifan/lenvatinib were anemia (69.2%), hypertension (58.9%), and diarrhea (52.7%); the cabozantinib arm saw frequent diarrhea (70.1%), hypertension (56 ...

Patients with resected renal cell carcinoma (RCC) receiving adjuvant durvalumab (Imfinzi) plus tremelimumab-actl (Imjudo) experienced early reductions in patient-reported quality of life (QoL), ...

While the combination of pembrolizumab with standard-of-care (SOC) radiation, and androgen deprivation therapy with or without olaparib (Lynparza) was found generally feasible in high-risk localized ...

While every patient with cancer will have psychosocial needs, understanding when to assess those needs and what professionals to connect a patient with are key to supporting patie ...

Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s ...

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...

With the addition of pembrolizumab to standard androgen deprivation therapy and radiation, immune-related adverse events are more likely.

The Oncology Nursing Society (ONS) is developing a skin of color toxicity photo repository with funding from a grant from La Roche-Posay to support oncology nurses in recognizing ...

Treatment with systemic intravenous olvimulogene nanivacirepvec (Olvi-Vec) led to promising preliminary results in patients with progressive non–small cell lung cancer (NSCLC) and progressive SCLC ...

Neoadjuvant EV plus pembrolizumab significantly improved event-free survival and overall survival vs gemcitabine/cisplatin in the phase 3 KEYNOTE-B15 trial. Neoadjuvant and adjuvant enfortumab vedotin ...